PHARMACEUTICALS


AXIM is actively involved in the research and development of innovative pharmaceutical delivery systems and cannabinoid-based APIs (active pharmaceutical ingredients) for treatment of conditions such as nausea and vomiting with chemotherapy and lack of appetite and cachexia in HIV/AIDS patients, pain and spasticity in restless leg syndrome (RLS), and spasticity and pain associated with multiple sclerosis(MS).

The first program the company is to conduct is MedChew™ with Dronabinol, which will undergo a bioequivalence study comparing it to FDA-approved dronabinol. Dronabinol was first introduced to the market in 1985 as a treatment for nausea and vomiting induced by chemotherapy. Dronabinol is a synthetic form of the commonly known cannabinoid tetrahydrocannabinol or THC. AXIM has currently formulated the drug and will perform a study on the release profile of the API through AXIM’s proprietary chewing gum delivery system. If bioequivalence is found between AXIM’s product and the product Marinol®, AXIM will seek FDA approval for the pharmaceutical bioequivalent.  

Additional clinical development programs that AXIM is targeting in the short and mid-term include: MedChew™ RL which will undergo clinical trials as a potential treatment for Restless Leg Syndrome (RLS), MedChew™ Rx which will target treatment of pain and spasticity associate with Multiple Sclerosis, and CanChew™ Rx which aims to treat drug-induced psychosis. These were selected due to the shorter timeline and overall ability to bring the drugs to the market. The research protocols are designed in strict adherence to the FDA/ EMA guidelines providing the best chance for a regulatory approval and accelerated market entry within 24-48 months.

These programs will utilize AXIM’s patented controlled-release, functional chewing gum delivery systems, which not only predictably provide its proprietary API’s but also adds fundamentally unique additional benefits via the physiological act of mastication. 

Additionally, AXIM has developed a unique extraction and purification technology for production of extremely pure—pharma-grade cannabinoids which meet the strictest cGMP standards.

AXIM’s strategy for 2019-2021 is built to position the Company as one of the world leaders in the clinical development of novel cannabinoid-based medicines which AXIM hopes to accomplish in the short and midterms.

MANAGEMENT
INVESTOR RELATIONS
RESEARCH & STRATEGY
Close Menu

Mr. Huemoeller has over 35 years experience in investment banking, finance, sales and marketing. Mr. Huemoeller began his career as an investment advisor in 1982 with M.L. Stern & Company a municipal bond firm in California and became a registered principal in 1985. He has previously been registered with various state insurance boards, as well as with the Chicago Board of Trade as a commodities broker. Mr. Huemoeller has worked for Smith Barney, Drexel Burnham, Prudential Securities, and Paine Webber and has extensive experience in stocks, bonds, commodities, mergers and acquisitions, leveraged buyouts and private placement transactions.

        Mr. Huemoeller has served on the Board of Directors of AXIM Biotechnologies Inc., as Chairman of the Audit Committee, since July 2017.  Mr. Huemoeller also currently serves on the Board of Directors of Pledge Petroleum Corporation another publicly traded company (PROP).  Mr. Huemoeller also currently serves on the Executive Committee of Kettner Investments, LLC, a Delaware Limited Liability Company that is a holding Company.  Since April 2015, Mr. Huemoeller has been the Chief Executive Officer and President of Air Water Earth Inc., an environmental technology company.  From March 2013 to January 2016, Mr. Huemoeller was Chairman, Chief Executive Officer and Chief Financial Officer, of Propell Technologies Group Inc., an oilfield service and technology Company wherein he oversaw the investment of over $18,000,000 into the Company, publicly traded under the symbol PROP on the OTCBB markets. From April 2012 to March 2013, Mr. Huemoeller was the President of Joshua Tree Capital Inc., an independent corporate finance advisory firm specializing in providing strategic capital formation guidance to public and private small cap oil and gas companies. From March 2009 to April 2012, Mr. Huemoeller was a FINRA-registered investment banker focused on all aspects of taking company’s public, deal structure, capital markets and Institutional placement of both debt and equity transactions with Buckman, Buckman and Reid. From August 2008 to March 2009, Mr. Huemoeller worked with Greenstone Holdings Group, LLC; an advisory firm with an emphasis on helping Chinese companies go public in the United States from January 2008 to July 2008, Mr. Huemoeller worked at Aspenwood Capital, a division of Green Drake Securities as an Investment Banker. Mr. Huemoeller formerly served on the Board of Directors of NatureWell Inc., a publicly traded company engaged in migraine relief OTC sublingual products. Mr. Huemoeller previously served as Chairman and CEO of HumWare Media Corp, a publicly traded software development, media and technology company which he started in 1998 and was responsible for acquisition strategies and the day-to-day corporate operations. Mr. Huemoeller is co-author of U.S. Patent #5,855,005. Mr. Huemoeller completed various studies in the Bachelor of Business Administration Program at the University of Minnesota and has previously held Series 3, 7, 24, 63 and 79 Securities Licenses.

Lekhram Changoer is the Chief Technology Officer of AXIM Biotechnologies, Inc. as of May 2014. He holds a Bachelor’s Degree in Analytical/Organic Chemistry and a Master’s Degree in Organic Chemistry. He was one of the founders of CanChew Biotechnologies, LLC in 2012 and is board member and partner of Sanammad Foundation and Sanammad Pharmaceuticals BV; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is the originator of multiple patents including patent-pending technology on chewing gum compositions comprising cannabinoids, together with his Sanammad partners. He has over 20 years of experience in the area of Sales & Marketing, R&D, product development, and quality assurance of technical, consumer healthcare and pharmaceutical products – all servicing European and other international markets. During his career he has co-founded different intellectual property-based pharmaceutical and dental companies in different stages from clinical development to the global sales of registered products.


Dr. Philip. A. Van Damme is Chief Scientific/Medical Officer of AXIM Biotechnologies Inc., as of May 2014. Prior to that, Dr. Van Damme was one of the founders and CSO of CanChew Biotechnologies LLC, in 2012. He is also one of the founders and President/Director of Sanammad Foundation and Sanammad Pharmaceuticals, both originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery systems. Dr. Van Damme possesses Dental and Medical Doctorates as well as a PhD in Medical Sciences, and has been actively involved in Research and Development in Dentistry, Medicine and Biotechnologies since 1983.

Dr. George E. Anastassov is the Founder of AXIM Biotechnologies, Inc. and Chairman of the Board. Prior to that Dr. Anastassov was one of the founders and the CEO of CanChew Biotechnologies, LLC in 2012. Dr. Anastassov is also one of the founders and a Board Member and a general partner of Sanammad Foundation and Sanammad Pharmaceuticals; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery system.

Dr. Anastassov possesses Medical and Dental Doctorates as well as an Executive MBA. Dr. Anastassov has been recognized in “Who’s Who in Medicine” as well as “Who’s Who in Business Professionals” numerous times. He is the recipient of multiple national and international professional and humanitarian awards. Dr. Anastassov has been actively involved in Research and Development in Medicine and Biotechnologies since 1987.